NCT06004700Active, not recruiting
Improving Virtual Care of Arthritis: Integrating a Smartphone App Into the EHR for Improved Timeliness of Visits
Improving Virtual Care of Arthritis: Integrating a Smartphone App Into the EHR for Improved Timeliness of Visits (An Electronic Health Record Integrated Application for Psoriatic Arthritis Patient Reported Outcomes) (RAPID-PsA)
Source: ClinicalTrials.gov · Last updated 26 Nov 2025
Brief summary (registry, in English)
The overall objective of this proposal is to test version 3.0 of the Arthritis smartphone app in a 12-month interrupted time series analysis (ITSA) design which will allow us to observe possible differences in visit frequency between the pre-and post-intervention periods as well as between the concurrent control group and those who receive the app. Our central hypothesis is that introduction of the app will reduce visit numbers per month in the group receiving the app, compared with a concurrent control group.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 278 (actual)
- First submitted
- 7 Aug 2023
- Start date
- 11 Apr 2024
- Primary completion date
- 1 Oct 2026
- Lead sponsor
- Brigham and Women's Hospital
- Diseases
- Psoriasis, Psoriatic arthritis
- NCT number
- NCT06004700
What you commit to
- Study type: Interventional
- Participants enrolled: 278
- From 11 Apr 2024 to the primary completion date, 1 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who do not plan on receiving follow-up care at the Brigham and Women's Arthritis Center will be excluded.
Who the study is looking for
- Be diagnosed with PsA by a board-certified rheumatologist and been seen at least twice in the prior year
- Own a smartphone with either an Android or iPhone operating system
- Be at least 18 years old
- Be English-speaking
- Using guselkumab, infliximab, golimumab or ustekinumab
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Brigham and Women's Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.